Neurocrine Biosciences Stock Forecast, Price & News

Neurocrine Biosciences (NASDAQ:NBIX) Frequently Asked Questions

Is Neurocrine Biosciences a buy right now?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Neurocrine Biosciences in the last year. There are currently 1 sell rating, 6 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Neurocrine Biosciences stock.
View analyst ratings for Neurocrine Biosciences or view top-rated stocks.

How has Neurocrine Biosciences' stock price been impacted by Coronavirus?

Neurocrine Biosciences' stock was trading at $85.90 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, NBIX stock has decreased by 7.2% and is now trading at $79.68.
View which stocks have been most impacted by COVID-19.

When is Neurocrine Biosciences' next earnings date?

Neurocrine Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, February 3rd 2022.
View our earnings forecast for Neurocrine Biosciences.

How were Neurocrine Biosciences' earnings last quarter?

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) posted its quarterly earnings results on Monday, November, 1st. The company reported $0.23 EPS for the quarter, missing the consensus estimate of $0.51 by $0.28. The company earned $296 million during the quarter, compared to analyst estimates of $297.02 million. Neurocrine Biosciences had a net margin of 41.59% and a trailing twelve-month return on equity of 35.89%. The business's revenue was up 14.5% on a year-over-year basis. During the same period in the prior year, the company posted ($0.62) earnings per share.
View Neurocrine Biosciences' earnings history.

What price target have analysts set for NBIX?

17 Wall Street analysts have issued 12 month price targets for Neurocrine Biosciences' shares. Their forecasts range from $76.00 to $150.00. On average, they expect Neurocrine Biosciences' stock price to reach $116.47 in the next year. This suggests a possible upside of 46.2% from the stock's current price.
View analysts' price targets for Neurocrine Biosciences or view top-rated stocks among Wall Street analysts.

Who are Neurocrine Biosciences' key executives?

Neurocrine Biosciences' management team includes the following people:

• Kevin Charles Gorman, Chief Executive Officer & Director
• Bill Wilson, Vice President-Information Technology & Operations
• Matthew C. Abernethy, Chief Financial Officer
• Dimitri E. Grigoriadis, Chief Research Officer
• Eiry W. Roberts, Chief Medical Officer

What is Kevin C. Gorman's approval rating as Neurocrine Biosciences' CEO?

11 employees have rated Neurocrine Biosciences CEO Kevin C. Gorman on Glassdoor.com. Kevin C. Gorman has an approval rating of 97% among Neurocrine Biosciences' employees. This puts Kevin C. Gorman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Neurocrine Biosciences' key competitors?

Some companies that are related to Neurocrine Biosciences include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Repligen (RGEN), Exact Sciences (EXAS), Novavax (NVAX), United Therapeutics (UTHR), Exelixis (EXEL) and Halozyme Therapeutics (HALO).
View all of NBIX's competitors.

What other stocks do shareholders of Neurocrine Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Neurocrine Biosciences investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Micron Technology (MU), Alibaba Group (BABA), Netflix (NFLX), AbbVie (ABBV), Walt Disney (DIS), Tesla (TSLA), Square (SQ) and salesforce.com (CRM).

What is Neurocrine Biosciences' stock symbol?

Neurocrine Biosciences trades on the NASDAQ under the ticker symbol "NBIX."

Who are Neurocrine Biosciences' major shareholders?

Neurocrine Biosciences' stock is owned by a variety of institutional and retail investors. Top institutional investors include Janus Henderson Group PLC (9.47%), Bellevue Group AG (3.17%), Bank of New York Mellon Corp (2.00%), Eaton Vance Management (1.99%), DSM Capital Partners LLC (1.59%) and Renaissance Technologies LLC (1.43%). Company insiders that own Neurocrine Biosciences stock include Darin Lippoldt, Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Haig P Bozigian, Julie Cooke, Kevin Charles Gorman, Kyle Gano, Malcolm Lloyd-Smith, Matt Abernethy and Stephen A Sherwin.
View institutional ownership trends for Neurocrine Biosciences.

Which institutional investors are selling Neurocrine Biosciences stock?

NBIX stock was sold by a variety of institutional investors in the last quarter, including ArrowMark Colorado Holdings LLC, Perceptive Advisors LLC, Polar Capital Holdings Plc, Bank of New York Mellon Corp, AustralianSuper Pty Ltd, SG Americas Securities LLC, New York State Common Retirement Fund, and Assenagon Asset Management S.A.. Company insiders that have sold Neurocrine Biosciences company stock in the last year include Dimitri E Grigoriadis, Eiry Roberts, Eric Benevich, Gary A Lyons, Julie Cooke, Kevin Charles Gorman, Malcolm Lloyd-Smith, and Matt Abernethy.
View insider buying and selling activity for Neurocrine Biosciences or view top insider-selling stocks.

Which institutional investors are buying Neurocrine Biosciences stock?

NBIX stock was acquired by a variety of institutional investors in the last quarter, including Eaton Vance Management, Nordea Investment Management AB, Deerfield Management Company L.P. Series C, Hood River Capital Management LLC, Balyasny Asset Management LLC, Balyasny Asset Management LLC, Point72 Asset Management L.P., and Jane Street Group LLC.
View insider buying and selling activity for Neurocrine Biosciences or or view top insider-buying stocks.

How do I buy shares of Neurocrine Biosciences?

Shares of NBIX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Neurocrine Biosciences' stock price today?

One share of NBIX stock can currently be purchased for approximately $79.68.

How much money does Neurocrine Biosciences make?

Neurocrine Biosciences has a market capitalization of $7.56 billion and generates $1.05 billion in revenue each year. The company earns $407.30 million in net income (profit) each year or $4.57 on an earnings per share basis.

How many employees does Neurocrine Biosciences have?

Neurocrine Biosciences employs 845 workers across the globe.

What is Neurocrine Biosciences' official website?

The official website for Neurocrine Biosciences is www.neurocrine.com.

Where are Neurocrine Biosciences' headquarters?

Neurocrine Biosciences is headquartered at 12780 EL CAMINO REAL, SAN DIEGO CA, 92130.

How can I contact Neurocrine Biosciences?

Neurocrine Biosciences' mailing address is 12780 EL CAMINO REAL, SAN DIEGO CA, 92130. The company can be reached via phone at (858) 617-7600, via email at [email protected], or via fax at 858-617-7602.